The autophagy-proteasome system represents the primary cellular machinery for clearing misfolded proteins and damaged organelles. In neurodegenerative diseases, both autophagy and proteasome function decline, leading to accumulation of toxic protein aggregates including amyloid-beta, tau, alpha-synuclein, and TDP-43[1][2]. This therapy proposes simultaneous activation of both pathways to achieve synergistic clearance of pathological protein species that neither pathway can handle alone[3].
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 7 | Dual activation concept is newer; components individually in trials |
| Mechanistic Rationale | 9 | Strong scientific basis for combining autophagy + proteasome |
| Addresses Root Cause | 9 | Targets protein aggregate clearance, fundamental problem |
| Delivery Feasibility | 6 | Large molecules may have BBB issues; small molecule approaches exist |
| Safety Plausibility | 7 | Autophagy modulation generally safe; proteasome excess needs monitoring |
| Combinability | 9 | Can combine with many other mechanisms |
| Biomarker Availability | 8 | LC3, p62, 20S proteasome activity measurable |
| De-risking Path | 7 | Components in development; combination needs validation |
| Multi-disease Potential | 9 | AD, PD, ALS, Huntington's - all protein aggregation diseases |
| Patient Impact | 8 | High potential for disease modification |
Total: 73/100
| Phase | Duration | Key Milestones |
|---|---|---|
| Discovery & Lead Optimization | 12-15 months | TFEB activator + proteasome enhancer combination screening, in vitro validation |
| IND-enabling studies | 12-15 months | GLP toxicology, CMC development, regulatory pre-IND meetings |
| Phase I | 12 months | Safety, dose-ranging in early AD/PD patients |
| Phase II | 15-18 months | Efficacy signal with LC3, p62, 20S proteasome biomarkers |
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| TFEB activator CNS penetration | Medium | High | Use blood-brain barrier-penetrant compounds, intranasal delivery |
| Combination toxicity | Medium | Medium | Staged toxicity testing, lowest effective doses |
| Biomarker assay validation | Medium | Low | CLIA-certified assay development in parallel |
| Competition with monotherapies | Low | Medium | Emphasize dual mechanism advantage over single-pathway approaches |
| Patient heterogeneity | Medium | Medium | Patient stratification by proteostasis biomarker profiles |